Brokers Set Expectations for SANA Q1 Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02.

A number of other research firms also recently issued reports on SANA. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They set a “buy” rating and a $7.00 target price for the company. Finally, Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $2.26 on Thursday. The firm has a market cap of $504.59 million, a P/E ratio of -1.61 and a beta of 1.63. The business’s 50 day moving average price is $2.98 and its 200-day moving average price is $3.19. Sana Biotechnology has a fifty-two week low of $1.52 and a fifty-two week high of $10.50.

Insider Activity

In related news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Sana Biotechnology by 10.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company’s stock worth $455,000 after acquiring an additional 25,383 shares during the last quarter. Vident Advisory LLC boosted its holdings in shares of Sana Biotechnology by 42.3% in the fourth quarter. Vident Advisory LLC now owns 43,291 shares of the company’s stock valued at $71,000 after purchasing an additional 12,861 shares during the period. Squarepoint Ops LLC grew its stake in Sana Biotechnology by 45.3% in the fourth quarter. Squarepoint Ops LLC now owns 178,431 shares of the company’s stock worth $291,000 after purchasing an additional 55,625 shares in the last quarter. Two Sigma Advisers LP raised its position in Sana Biotechnology by 677.0% during the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company’s stock valued at $341,000 after purchasing an additional 182,100 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock worth $783,000 after acquiring an additional 334,042 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.